Science Corporation valued at $3.5 billion after $400 million funding round
Science Corporation, the medical technology startup founded in 2021 by former Neuralink president Max Hodak, has raised $400 million in a Series D round. A person familiar with the deal told TechCrunch that the investment valued the company at $3.5 billion. Participants included Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator, and PLC Neurotech.
The company’s first product, PRIMA, is a wearable and implantable chip designed to help people with age-related macular degeneration regain some vision. It is approved in Europe and available in Germany, and is being tested for additional conditions. Hodak said the device is now being trialled for Stargardt’s disease. Science plans to pursue US access through the FDA’s Humanitarian Device Exemption, after persuading the agency that advanced macular degeneration affecting both eyes is sufficiently uncommon for that pathway.
The company is also developing a bio-hybrid sensor combining cultured neurons with silicon to connect directly to the brain. Science is designing initial human trials with Yale neurosurgery professor Murat Günel, who said the technology could eventually have applications including Parkinson’s disease and other neurological conditions.
Written by Sakhanda Wire AI from reporting by TechCrunch. Facts, quotes and full context are in the original article below.